Latest News Releases

PTA-Adhoc: Biofrontera AG: Initial public offering price of Biofrontera Inc. IPO

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta002/29.10.2021/03:40) - Leverkusen, Germany, October 29, 2021- On July 6, 2021, Biofrontera AG announced that its US-subsidiary Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States ("IPO"). On October 27, 2021, Biofrontera Inc. announced that up to 3,565,000 units ("Units") consisting of one new Biofrontera Inc. share and one warrant entitling the holder to one additional new Biofrontera Inc. share shall be offered in the IPO. The public offering price of a Unit is allocated between the share and the warrant. Each warrant has an exercise price equal to the initial public offering price and expires five years from the date of issuance.

Biofrontera Inc. has now set that 3,600,000 Units will be offered at a public offering price of USD 5.00 per Unit, of which USD 4.99 per Unit is allocated to one share and USD 0.01 per Unit is allocated to one warrant.

In addition, Biofrontera has granted the underwriters a 30-day option to purchase additional 540,000 shares of its common stock and/or warrants to purchase up to an additional 540,000 of its common stock, at the initial public offering price, less the underwriting discounts and commissions.

Biofrontera Inc. expects gross proceeds from the IPO (excluding the over-allotment), before deduction of underwriting discounts and commissions and offering expenses, to be USD 18,000,000.

This offering is being made only by means of a prospectus which has been filed with the U.S. Securities and Exchange Commission as part of an effective registration statement.

This public disclosure of inside information according to article 17 MAR shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: ]

Financial announcements